Last 25 quarters of trend data · Healthcare · Biotechnology
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | -5.33 | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/S Ratio | 3.77 | 1.57 | 2.36 | 2.49 | 1.83 | 1.69 | 3.38 | 4.51 | 3.31 | 4.47 | 2.92 | 4.93 | 5.95 |
| — | -7.0% | -30.0% | -44.7% | -44.7% | -62.2% | +15.6% | -8.6% | -44.3% | -23.5% | +26.9% | +12.3% | +66.6% | |
| P/B Ratio | 1.89 | 1.12 | 1.27 | 0.96 | 0.74 | 0.60 | 1.32 | 1.92 | 1.25 | 1.48 | 1.10 | 1.48 | 1.83 |
| — | +87.8% | -4.1% | -49.9% | -40.7% | -59.5% | +20.4% | +29.8% | -31.4% | -28.0% | -47.3% | -63.0% | -59.2% | |
| P/FCF | — | 24.50 | — | — | — | — | — | 82.96 | 30.85 | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBITDA | 9.58 | 5.87 | 9.07 | 0.40 | — | — | — | — | 47.73 | — | 38.66 | — | 2277.39 |
| — | — | — | — | — | — | — | — | -97.9% | — | +904.0% | — | +49998.1% | |
| EV / EBIT | — | 98.53 | — | — | — | — | — | — | — | — | 0.34 | — | — |
| — | — | — | — | — | — | — | — | — | — | -92.3% | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
Maravai LifeSciences Holdings, Inc.'s operating margin was 1.1% in Q1 2026, up 14.6 pp QoQ and up 106.0 pp YoY. The trailing four-quarter average of 31.3% exceeds the current quarter, suggesting the latest result may reflect seasonal weakness or a one-off headwind. Gross margin expanded 210.4% YoY, indicating pricing power or improving input costs.
| Metric | TTM | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 18.0% | 51.2% | 24.5% | 13.6% | 16.4% | 16.5% | 33.6% | 43.5% | 47.9% | 40.3% | 52.6% | 45.1% | 37.2% |
| — | +210.4% | -27.0% | -68.8% | -65.8% | -59.1% | -36.1% | -3.6% | +28.6% | -29.8% | -28.8% | -43.6% | -56.0% | |
| Operating Margin | -3.6% | 1.1% | -13.5% | 277.3% | -139.8% | -104.9% | -67.6% | -259.4% | -13.0% | -29.4% | -9.6% | -23.1% | -16.9% |
| — | +101.0% | +80.0% | +206.9% | -979.1% | -257.1% | -601.0% | -1024.9% | +23.1% | -1016.9% | -118.1% | -137.7% | -122.6% | |
| Net Margin | -70.4% | -5.7% | -71.6% | -61.4% | -83.5% | -63.9% | -46.4% | -151.9% | -10.3% | -18.8% | -142.9% | -9.7% | -9.5% |
| — | +91.1% | -54.4% | +59.6% | -708.3% | -239.6% | +67.6% | -1471.8% | -8.9% | -22092.5% | -877.4% | -141.6% | -132.3% |
| Metric | TTM | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -27.5% | -1.0% | -8.9% | -5.7% | -7.9% | -5.4% | -4.4% | -14.3% | -1.0% | -1.5% | -12.6% | -0.7% | -0.7% |
| — | +81.4% | -101.9% | +60.2% | -712.5% | -250.9% | +65.1% | -1874.3% | -34.2% | -20728.4% | -392.4% | -113.1% | -107.3% | |
| ROA | -14.7% | -0.5% | -4.4% | -2.9% | -4.3% | -3.0% | -2.3% | -7.3% | -0.5% | -0.8% | -5.6% | -0.3% | -0.3% |
| — | +83.5% | -92.6% | +59.7% | -713.1% | -269.4% | +59.5% | -2447.9% | -83.6% | -28306.9% | -439.8% | -114.2% | -108.4% | |
| ROIC | -1.2% | 0.3% | -2.4% | 22.0% | -8.4% | -5.9% | -4.7% | -18.6% | -0.9% | -1.8% | -0.6% | -1.2% | -1.0% |
| — | +104.2% | +47.8% | +218.2% | -813.3% | -235.2% | -661.7% | -1400.6% | +3.9% | -904.9% | -106.0% | -110.7% | -105.4% |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
Maravai LifeSciences Holdings, Inc.'s Debt/EBITDA ratio is 2.9x, down from 4.5x last quarter — at a moderate level that warrants monitoring.
| Metric | TTM | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.10 | 0.10 | 0.10 | 0.08 | 0.78 | 0.70 | 0.65 | 0.92 | 0.72 | 0.72 | 0.77 | 0.69 | 0.69 |
| — | -86.3% | -85.4% | -90.9% | +7.4% | -3.4% | -15.6% | +32.8% | +5.2% | +8.0% | +19.6% | +8.6% | -0.2% | |
| Debt / EBITDA | 0.66 | 2.92 | 4.45 | 0.27 | — | — | — | — | 111.59 | — | 104.80 | — | 3354.72 |
| — | — | — | — | — | — | — | — | -96.7% | — | +2035.7% | — | +119150.5% | |
| Current Ratio | 6.60 | 5.91 | 6.60 | 5.29 | 5.16 | 5.96 | 7.53 | 10.74 | 10.00 | 11.32 | 8.00 | 8.96 | 9.33 |
| — | -0.9% | -12.4% | -50.7% | -48.4% | -47.4% | -5.9% | +19.9% | +7.1% | +84.6% | +3.9% | +24.0% | +38.3% | |
| Quick Ratio | 5.69 | 4.96 | 6.60 | 4.56 | 4.49 | 5.17 | 6.65 | 9.94 | 9.28 | 10.47 | 7.41 | 8.33 | 8.70 |
| — | -4.1% | -0.9% | -54.2% | -51.6% | -50.6% | -10.3% | +19.4% | +6.6% | +84.0% | +1.5% | +24.6% | +40.0% | |
| Interest Coverage | -7.71 | 0.13 | -8.61 | -5.60 | -9.88 | -6.77 | -3.13 | -11.88 | -0.42 | -1.06 | 43.61 | -0.77 | -0.90 |
| — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 25 years · Updated daily
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorDCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare business quality, growth, and profitability against top sector peers.
Start ComparisonQuick answers to the most common questions about buying MRVI stock.
Maravai LifeSciences Holdings, Inc.'s current P/E is -5.3x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Maravai LifeSciences Holdings, Inc.'s current operating margin is -3.6%. Margins have been expanding over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Maravai LifeSciences Holdings, Inc.'s business trajectory between earnings reports.